Hofseth Biocare Asa Quote - 0Q6H

	Real-time Prices	Level 2
Australian Stock Exchange

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

2.00

Bid

0.00

Offer

0.00

Volume

0.00

0.00 Day's Range 0.00

2.00 52 Week Range 2.00

Market Cap

790.162M

Previous Close

2.00

Open

Last Trade

(O)

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

2,310

Shares Outstanding

395,081,000

Dividend Yield

PE Ratio

-7.41

Earnings Per Share (EPS)

-0.27

Revenue

218.51M

Net Profit

-106.68M

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.hofsethbiocare.com

Headquarters

Alesund, Nor

Founded

Hofseth Biocare Asa is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker 0Q6H. The last closing price for Hofseth Biocare Asa was kr2. Over the last year, Hofseth Biocare Asa shares have traded in a share price range of kr 2.00 to kr 2.00.

Hofseth Biocare Asa currently has 395,081,000 shares in issue. The market capitalisation of Hofseth Biocare Asa is kr790.16 million. Hofseth Biocare Asa has a price to earnings ratio (PE ratio) of -7.41.

Hofseth Biocare ASA: THIRD QUARTER 2024 FINANCIAL REPORT

Hofseth Biocare ASA: THIRD QUARTER 2024 FINANCIAL REPORT HBC had gross operating revenues of NOK 67.9m (49.9m) in the third quarter and NOK 200.6m (171.1m) in the first nine months. The operating...

Hofseth Biocare ASA: CFO RESIGNATION

Hofseth Biocare ASA: CFO RESIGNATION Christel Elise Kanli has decided to step down as Chief Financial Officer (CFO) of Hofseth BioCare ASA (“HBC”) to pursue opportunities outside of the company...

Hofseth Biocare ASA: HBC IMMUNOLOGY COMPLETES IN VIVO DRUG LEAD STUDIES FOR PROSTATE CANCER TREATMENT

Hofseth Biocare ASA: HBC IMMUNOLOGY COMPLETES IN VIVO DRUG LEAD STUDIES FOR PROSTATE CANCER TREATMENT Ålesund, Norway, 8 October 2024. HBC Immunology (HBCI) is pleased to announce the successful...

Hofseth Biocare ASA: SECOND QUARTER AND HALF YEAR 2024 FINANCIAL REPORT

Hofseth Biocare ASA: SECOND QUARTER AND HALF YEAR 2024 FINANCIAL REPORT HBC had gross operating revenues of NOK 80.4m (76.4m) in the second quarter and NOK 132.8m (121.2m) for the half year...

Hofseth Biocare ASA: GROUNDBREAKING STUDY REVEALS HOFSETH BIOCARE’S FULL SPECTRUM OMEGAS OMEGO SUPPORTS COVID-19 RECOVERY

Hofseth Biocare ASA: GROUNDBREAKING STUDY REVEALS HOFSETH BIOCARE’S FULL SPECTRUM OMEGAS OMEGO SUPPORTS COVID-19 RECOVERY Ålesund, Norway, 14 August, 2024 - Hofseth BioCare (HBC), a leader in...

Hofseth Biocare ASA: HBC discovers new drug candidate for asthma and transfers it to HBC Immunology Inc.

Hofseth Biocare ASA: HBC discovers new drug candidate for asthma and transfers it to HBC Immunology Inc. Ålesund, 02.07.24, Hofseth BioCare ASA ("HBC" or the "Company"), a global leader in marine...

Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY

Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY Hofseth BioCare ASA (HBC) is delighted to announce the appointment of Lithy One-Health Group Technology Co. Ltd...

Hofseth Biocare ASA: FIRST QUARTER 2024 FINANCIAL REPORT

Hofseth Biocare ASA: FIRST QUARTER 2024 FINANCIAL REPORT The first quarter of 2024 continued on the positive trend for HBC. Sales revenues came in at NOK 52m vs NOK 44m last year, a growth of 17...

Hofseth Biocare ASA: Annual General Meeting completed

Hofseth Biocare ASA: Annual General Meeting completed Hofseth BioCare ASA held its Annual General Meeting on 10 May 2024. 270,174,810 shares, amounting to 68.38 per cent of the share capital, were...

Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2024

Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2024 The Annual General Meeting of Hofseth BioCare ASA for 2024 will be held at the company's premises at Keiser Wilhelms gate 24, 6003...

Hofseth Biocare ASA: THIRD QUARTER 2024 FINANCIAL REPORT

Hofseth Biocare ASA: THIRD QUARTER 2024 FINANCIAL REPORT HBC had gross operating revenues of NOK 67.9m (49.9m) in the third quarter and NOK 200.6m (171.1m) in the first nine months. The operating...

Hofseth Biocare ASA: CFO RESIGNATION

Hofseth Biocare ASA: HBC IMMUNOLOGY COMPLETES IN VIVO DRUG LEAD STUDIES FOR PROSTATE CANCER TREATMENT

Hofseth Biocare ASA: HBC IMMUNOLOGY COMPLETES IN VIVO DRUG LEAD STUDIES FOR PROSTATE CANCER TREATMENT Ålesund, Norway, 8 October 2024. HBC Immunology (HBCI) is pleased to announce the successful...

Hofseth Biocare ASA: SECOND QUARTER AND HALF YEAR 2024 FINANCIAL REPORT

Hofseth Biocare ASA: SECOND QUARTER AND HALF YEAR 2024 FINANCIAL REPORT HBC had gross operating revenues of NOK 80.4m (76.4m) in the second quarter and NOK 132.8m (121.2m) for the half year...

Hofseth Biocare ASA: GROUNDBREAKING STUDY REVEALS HOFSETH BIOCARE’S FULL SPECTRUM OMEGAS OMEGO SUPPORTS COVID-19 RECOVERY

Hofseth Biocare ASA: GROUNDBREAKING STUDY REVEALS HOFSETH BIOCARE’S FULL SPECTRUM OMEGAS OMEGO SUPPORTS COVID-19 RECOVERY Ålesund, Norway, 14 August, 2024 - Hofseth BioCare (HBC), a leader in...

Period	Open	High	Low	Avg. Daily Vol	VWAP
1	2	2	2	0	0	DE
4	2	2	2	0	0	DE
12	2	2	2	2310	2	DE
26	2	2	2	1245	2	DE
52	2	2	2	1151	2	DE
156	2	2	2	646	2	DE
260	2	2	2	2644	2	DE

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
PIPPipehawk Plc	2.00p (48.15%)	566.95k
KBTK3 Business Technology Group Plc	92.50p (48.00%)	9.55k
CMETCapital Metals Plc	2.10p (31.25%)	2.69M
APQApq Global Limited	6.50p (30.00%)	35k
GBPGlobal Petroleum Limited	0.35p (20.69%)	67.7M
GRLGoldstone Resources Limited	1.15p (-26.98%)	4.95M
ARBArgo Blockchain Plc	6.125p (-24.38%)	46.97M
HSSHss Hire Group Plc	5.00p (-16.11%)	596.73k
BBBBigblu Broadband Plc	35.00p (-14.63%)	236.04k
TRYBTribe Technology Plc	1.65p (-13.16%)	256.38k
ORCPOracle Power Plc	0.0375p (17.19%)	1.34B
PREMPremier African Minerals Limited	0.056p (2.75%)	357.79M
TRPTower Resources Plc	0.0305p (-1.61%)	240.28M
NTVONativo Resources Plc	0.0025p (0.00%)	231.54M
NTOGNostra Terra Oil And Gas Company Plc	0.0255p (0.00%)	126.93M